The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM.
Expert Opin Drug Saf · review; journal article · DOI 10.1517/14740338.2016.1135899 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för rolapitant. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
12 träffarState of the Art Antiemetic Therapy for Cancer Patients.
Lau TK, Yip CH, Yeo W.
Curr Oncol Rep · review; journal article · DOI 10.1007/s11912-015-0486-5Rolapitant: first global approval.
Syed YY.
Drugs · review; journal article · DOI 10.1007/s40265-015-0485-8Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
Rojas C, Slusher BS.
Cancer Treat Rev · review; journal article · DOI 10.1016/j.ctrv.2015.09.005Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM.
Expert Rev Anticancer Ther · comparative study; journal article · DOI 10.1586/14737140.2015.1088787Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig ID.
Lancet Oncol · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1470-2045(15)00034-0Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM.
Lancet Oncol · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/s1470-2045(15)00035-2Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Rapoport B, Chua D, Poma A, Arora S, Wang Y, Fein LE.
Support Care Cancer · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1007/s00520-015-2738-1Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review.
Jordan K, Jahn F, Aapro M.
Ann Oncol · review; journal article · DOI 10.1093/annonc/mdv138New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting.
Schwartzberg LS, Rugo HS, Aapro MS.
Clin Adv Hematol Oncol · research support, non-u.s. gov't; journal articleClinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting.
Morrow GR, Navari RM, Rugo HS.
Clin Adv Hematol Oncol · research support, non-u.s. gov't; journal articleRolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.
Duffy RA, Morgan C, Naylor R, Higgins GA, Varty GB, Lachowicz JE, Parker EM.
Pharmacol Biochem Behav · journal article · DOI 10.1016/j.pbb.2012.03.021